Browsing ODA Open Digital Archive by Author "Bolstad, Nils"
Now showing items 1-4 of 4
-
The effect of infliximab in patients with chronic low back pain and Modic changes (the BackToBasic study): study protocol of a randomized, double blind, placebo-controlled, multicenter trial
Gjefsen, Elisabeth; Bråten, Lars Christian Haugli; Goll, Guro Løvik; Wigemyr, Monica; Bolstad, Nils; Valberg, Morten; Schistad, Ellina Iordanova; Marchand, Gunn Hege; Granviken, Fredrik; Selmer, Kaja Kristine; Johanessen, Anne Froholdt; Haugen, Anne Julsrud; Dagestad, Magnhild Hammersland; Vetti, Nils; Bakland, Gunnstein; Lie, Benedicte Alexandra; Haavardsholm, Espen A.; Nilsen, Aksel Thuv; Holmgard, Thor Einar; Kadar, Thomas; Kvien, Tore Kristian; Skouen, Jan Sture; Grøvle, Lars; Brox, Jens Ivar; Espeland, Ansgar; Storheim, Kjersti; Zwart, John-Anker (BMC Musculoskeletal Disorders;21, Article number: 698 (2020), Journal article; Peer reviewed, 2020-10-21)Background: Low back pain is common and a significant number of patients experience chronic low back pain. Current treatment options offer small to moderate effects. Patients with vertebral bone marrow lesions visualized ... -
Interferens fra revmatoid faktor i multiplex cytokinanalyser
Mehus, Lise Larsen (Master thesis, 2024)Feilmåling forårsaket av revmatoid faktor (RF), som ofte finnes i blod hos pasienter med revmatoid artritt (RA), er en kjent problemstilling i immunoassays. Men diagnostiske analyser er nå ofte beskyttet ved at reagensene ... -
Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study
Helm, Thea Elisabeth; Høivik, Marte Lie; Anisdahl, Karoline; Buer, Lydia Celine Tansem; Warren, David; Bolstad, Nils; Småstuen, Milada Cvancarova; Moum, Bjørn Allan; Medhus, Asle Wilhelm (Peer reviewed; Journal article, 2024)Background: Vedolizumab has since 2021 been available as a subcutaneous formulation. We aimed to assess 18-month drug persistence and possible predictive factors associated with discontinuation, safety, serum drug profile, ... -
Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring
Wiken, Thea H.; Høivik, Marte Lie; Buer, Lydia Celine Tansem; Warren, David J.; Bolstad, Nils; Moum, Bjørn Allan; Anisdahl, Karoline; Småstuen, Milada Cvancarova; Medhus, Asle Wilhelm (Peer reviewed; Journal article, 2023)Objective: Vedolizumab (VDZ) for subcutaneous (SC) administration has recently become available. We aimed to assess feasibility, safety and clinical outcome when switching from intravenous (IV) to SC VDZ maintenance ...